PPI/NSAID Combinations Could Have Smoother Route To Approval After Review Division Harmonization
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA will ask its Gastrointestinal Drugs Advisory Committee at a Nov. 4 meeting whether it agrees that endoscopically diagnosed ulcers are an appropriate surrogate endpoint, which would make large, pre-approval GI outcomes studies unnecessary.